# B-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION

> **NIH NIH N01** · VANDERBILT UNIVERSITY MEDICAL CENTER · 2022 · $2,000,000

## Abstract

In 2022, monkeypox infections began to spread globally and was declared a United States public health emergency. There is an urgent need for identification of prophylactic and therapeutic approaches for prevention and treatment of monkeypox infection. The goal of this contract is to extend the validation and identification of antibody functions for monkeypox virus (MPXV) A six antibody cocktail, previously identified by the Contractor under this contract program, has shown promise for prevention and treatment of monkeypox in small animal models. However, the inclusion of six antibodies introduces significant manufacturing and regulatory challenges and there is a need to demonstrate functional utility of each antibody in prevention/therapy for MPXV infection.

## Key facts

- **NIH application ID:** 10706905
- **Project number:** 75N93019C00074-P00010-9999-3
- **Recipient organization:** VANDERBILT UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** James E Crowe
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,000,000
- **Award type:** —
- **Project period:** 2019-09-16 → 2023-09-15

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10706905

## Citation

> US National Institutes of Health, RePORTER application 10706905, B-CELL EPITOPE DISCOVERY AND MECHANISMS OF ANTIBODY PROTECTION (75N93019C00074-P00010-9999-3). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10706905. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*